CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS...
Phase 4
London, United Kingdom and 16 other locations
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
London, United Kingdom and 156 other locations
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS...
Phase 1
London, Greater London, United Kingdom
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is imp ...
London, United Kingdom
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
London, United Kingdom and 72 other locations
effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...
Phase 3
London, London, City Of, United Kingdom and 20 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
London, United Kingdom and 46 other locations
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...
Phase 3
London, United Kingdom and 105 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
London, United Kingdom and 239 other locations
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The st...
Phase 1
London, United Kingdom
Clinical trials
Research sites
Resources
Legal